Monalizumab
(Redirected from
IPH2201
)Humanized | |
|---|---|
| Target | NKG2A |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]
Mechanism of action
Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5][6]
References
- ^ A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
- ^ IPH2201 studies
- ^ First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
- ^ AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
- ^ "monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.
- PMID 31623687.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |